Keeping you up to date with the latest clinical trial information
Menopause & Hormone Replacement Therapy
 |
Hypertension in Postmenopausal Women
The incidence of cardiovascular and cerebrovascular diseases in women is low before the menopause but after the age of 50 years they become the leading cause of mortality and morbidity for women living in most developed countries.
|
VMS Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone
The primary purpose of this study is to determine the effects of a full dose (300 mg at hs) of oral micronized progesterone (OMP) on vasomotor symptoms [VMS] (hot flushes/night sweats), on forearm blood flow and on lipid levels and blood pressure in menopausal women without cardiovascular disease and with moderate to severe VMS.
Related Articles
Study of Paxil Use in Menopausal Women
To evaluate the efficacy, safety, and tolerability of Paroxetine treatment in perimenopausal and postmenopausal women who present with menopause-related symptoms after discontinuing hormone therapy (HT), in the presence or absence of concomitant symptoms of depression or anxiety.
Related Articles
A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041 for Treatment of Vulvovaginal Atrophy
This is a four-arm, randomized, double-blind, parallel group, placebo-controlled study to compare the effects of two doses of DR-2041 Vaginal Cream on vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.
Related Articles
currently marketed femhrt 1 mg/5 mcg) is indicated for the treatment
of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis.
The company expects to launch the new low-dose Femhrt 0.5 mg/2.5 mcg in the second quarter of 2005.
